MoneyWorks4Me

Windlas Biotech - Quaterly Results

08 Feb 2023 Evaluate
The quarter ended December 2022 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 1197.04 millions.A humble growth in net profit of 10.50% reported in the quarter ended December 2022 to Rs. 91.88  millions from Rs. 83.15 millions.Operating profit surged to 161.11 millions from the corresponding previous quarter of 148.36 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 1197.04 1175.91 1.80 3723.70 3437.99 8.31 4659.30 4276.02 8.96
Other Income 21.62 17.93 20.58 76.31 37.01 106.19 67.06 30.94 116.74
PBIDT 161.11 148.36 8.59 514.31 423.11 21.55 596.01 577.86 3.14
Interest 1.57 2.11 -25.59 6.22 11.29 -44.91 14.17 12.90 9.84
PBDT 159.54 146.25 9.09 508.09 411.82 23.38 581.84 241.45 140.98
Depreciation 31.35 31.45 -0.32 87.96 92.45 -4.86 121.47 129.65 -6.31
PBT 128.19 114.80 11.66 420.13 319.37 31.55 460.37 111.80 311.78
TAX 36.31 31.65 14.72 108.16 86.09 25.64 74.76 61.70 21.17
Deferred Tax 8.65 4.12 109.95 6.75 1.93 249.74 -26.57 13.28 -300.08
PAT 91.88 83.15 10.50 311.97 233.28 33.73 385.61 50.10 669.68
Equity 107.21 108.97 -1.62 108.97 108.97 0.00 108.97 64.11 69.97
PBIDTM(%) 13.46 12.62 6.68 13.81 12.31 12.23 12.79 13.51 -5.34
Peers
Company Name CMP
Sun Pharma. Inds. 1810.00
Dr. Reddys Labs. 1200.10
Cipla 1346.85
Lupin 2029.00
Zydus Lifesciences 1145.25
View more..